A Phase I Study to Determine Safety, Tolerability and Preliminary Anti-Staphylococcal Activity of Intranasally Administered XF-73.

Trial Profile

A Phase I Study to Determine Safety, Tolerability and Preliminary Anti-Staphylococcal Activity of Intranasally Administered XF-73.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2010

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2010 Results were reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 15 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top